{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:12:06Z","timestamp":1790691126238,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cmi.2021.02.013","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:01:52Z","timestamp":1614402112000},"page":"791.e5-791.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns"],"prefix":"10.1016","volume":"27","author":[{"given":"Anthony","family":"Touafchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.02.013_bib1","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cmi.2021.02.013_bib2","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.cgh.2020.07.050","article-title":"Hepatic disorders with the use of remdesivir for coronavirus 2019","volume":"18","author":"Montastruc","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2021.02.013_bib3","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2021.02.013_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/ebmed-2017-110885","article-title":"Rare adverse events in clinical trials: understanding the rule of three","volume":"23","author":"Onakpoya","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib7","article-title":"Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: a comprehensive pharmacovigilance analysis of pre-COVID-19 reports","author":"Goldman","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2021.02.013_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.27488","article-title":"Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C","volume":"62","author":"Ahmad","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.02.013_bib9","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMc1505967","article-title":"Bradyarrhythmias associated with sofosbuvir treatment","volume":"373","author":"Fontaine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28752","article-title":"Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in Guinea pigs and rhesus monkeys","volume":"64","author":"Regan","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2021.02.013_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/FJC.0b013e3181e0f8b2","article-title":"The mechanism of the negative chronotropic and dromotropic actions of adenosine 5\u2019-triphosphate in the heart: an update","volume":"56","author":"Pelleg","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cmi.2021.02.013_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","article-title":"Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture?","volume":"36","author":"Coloma","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.cmi.2021.02.013_bib13","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jamainternmed.2014.3270","article-title":"Finding meaningful patterns in adverse drug event reports","volume":"174","author":"Gagne","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib14","first-page":"2591","article-title":"Risk of adverse drug events following the virtual addition of covid-19 repurposed drugs to drug regimens of frail older adults with polypharmacy","volume":"9","author":"Al Rihani","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cmi.2021.02.013_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs","volume":"14","author":"Michaud","year":"2020","journal-title":"Clin Transl Sci"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:29:34Z","timestamp":1761118174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2100094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1198743X2100094X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.02.013","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}